Aptamers in Ocular Disease Treatment
Author Information
Author(s): Wang Tao, Veedu Rakesh Naduvile
Primary Institution: The Kids Research Institute Australia, The University of Western Australia
Hypothesis
Can in vivo SELEX be used to develop RNA aptamers that effectively penetrate ocular barriers for treatment?
Conclusion
The study suggests that in vivo SELEX can lead to the development of aptamers that may provide a less invasive and more effective treatment for ocular diseases.
Supporting Evidence
- Ocular diseases are projected to affect over 280 million people by 2040.
- Current treatments often involve invasive procedures leading to poor patient compliance.
- The study identified five different aptamer families based on nucleotide similarity.
- Apt2 and Apt5 showed significant differences in biodistribution between ocular and control tissues.
- Further research is needed to validate findings in human subjects.
Takeaway
Scientists are trying to create tiny molecules that can help treat eye diseases without needing painful injections. They found some that work better than others.
Methodology
The study used in vivo SELEX in rats to select RNA aptamers and analyzed them using next-generation sequencing.
Potential Biases
Potential biases in aptamer efficacy due to differences in incubation schemes or PCR processes.
Limitations
Further research is needed to assess the long-term safety and efficacy of these aptamers in humans.
Participant Demographics
Rats were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website